Carrie B Klonel, DO in Antrim, NH - Family Medicine

Carrie B Klonel, DO is a Family Medicine physician based in Antrim, New Hampshire. Carrie B Klonel is licensed to practice in New Hampshire (license number 12795) and her current practice location is 12 Elm St, Antrim, New Hampshire. She can be reached at her office (for appointments etc.) via phone at (603) 588-4200.

NPI number for Carrie B Klonel is 1821060203 and her current mailing address is 12 Elm St, Antrim, New Hampshire. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1821060203.

Contact Information

	Carrie B Klonel, DO
	12 Elm St, Antrim, NH 03440-3916
	(603) 588-4200
	(603) 588-4089

Physician's Profile

Full Name	Carrie B Klonel
Gender	Female
Speciality	Family Medicine
Location	12 Elm St, Antrim, New Hampshire
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1821060203
Provider Enumeration Date: 02/01/2006
Last Update Date: 11/09/2015

Medical Identifiers

Medical identifiers for Carrie B Klonel such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1821060203	NPI	-	NPPES
30212207	Medicaid	NH

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	12795 (New Hampshire)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Carrie B Klonel is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Carrie B Klonel, DO 12 Elm St, Antrim, NH 03440-3916 Ph: (603) 588-4200	Carrie B Klonel, DO 12 Elm St, Antrim, NH 03440-3916 Ph: (603) 588-4200

News Archive

BTG launches Voraxaze for treatment of toxic plasma methotrexate

BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.

WHO presents '2012 In Review' photo essay

"Key public health milestones were reached in 2012, including the end of polio transmission in India and meeting the Millennium Development Goal target on drinking water ahead of schedule," the WHO reports in a summary of a "2012 In Review" photo essay.

Covidien launches V-Loc 90 knotless wound closure device

Covidien, a leading global provider of healthcare products, today announced the global launch of the V-Loc 90 device, expanding its family of V-Loc absorbable wound closure devices. This latest addition to Covidien's knotless wound closure product line received 510(k) clearance from the U.S. Food and Drug Administration on May 11, 2010.

Revamped South African National AIDS Council begins work reviewing national plan

South Africa "recently unveiled" a "newly reformed" South African National AIDS Council (SANAC), "coinciding with the announcement that the country has achieved universal access to HIV treatment," PlusNews reports.

Obama's interview on health and fitness priorities to be published in a health magazine

President Barack Obama and First Lady Michelle Obama speak candidly about health and fitness priorities for the country and their family in exclusive interviews that will appear in the October 2009 issues of Men's Health and Women's Health, respectively. The October issues hit newsstands on Tuesday, September 15.

Carrie B Klonel, DO - Family Medicine in Antrim, NH